Abstract
Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.
MeSH terms
-
Acute Disease
-
Aged
-
Benzopyrans / administration & dosage*
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / etiology
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Humans
-
Neuroprotective Agents / administration & dosage*
-
Serotonin Receptor Agonists / administration & dosage*
-
Stroke / complications
-
Stroke / drug therapy*
-
Thiazoles / administration & dosage*
-
Treatment Outcome
Substances
-
Benzopyrans
-
Neuroprotective Agents
-
Serotonin Receptor Agonists
-
Thiazoles
-
repinotan hydrochloride